Fierce Biotech June 21, 2024
Switzerland’s Melodia Therapeutics has signed a $275 million biobucks deal to get its hands on Alivexis’ preclinical cathepsin C inhibitor.
Melodia said it will “rapidly initiate” IND-enabling activities for the candidate, dubbed MDI-0151, in preparation for phase 1/2a study in a range of refractory inflammatory diseases caused by excessive activation of neutrophils, such as anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.
Researchers have already suggested that inhibiting the activity of cathepsin C, a lysosomal exo-cysteine protease, has the potential to treat various types of inflammatory disease, including bronchiectasis and ANCA-associated vasculitis.
Inhibiting cathepsin C is believed to have little effect on the immune function of neutrophils, meaning MDI-0151 has potential to treat various immune and inflammatory diseases without compromising the immune...
Today's Sponsors
Today's Sponsor